Trials / Completed
CompletedNCT04842201
Single Ascending Dose Study of CM326 in Healthy Volunteers
A Phase 1, Randomized, Placebo-Controlled, Double-blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CM326 in Adult Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CM326 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CM326 | subcutaneous injection |
| DRUG | Placebo | subcutaneous injection |
Timeline
- Start date
- 2021-04-13
- Primary completion
- 2021-09-28
- Completion
- 2021-09-28
- First posted
- 2021-04-13
- Last updated
- 2022-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04842201. Inclusion in this directory is not an endorsement.